AU2002211662A1 - Nf-kappab inhibitors - Google Patents

Nf-kappab inhibitors

Info

Publication number
AU2002211662A1
AU2002211662A1 AU2002211662A AU1166202A AU2002211662A1 AU 2002211662 A1 AU2002211662 A1 AU 2002211662A1 AU 2002211662 A AU2002211662 A AU 2002211662A AU 1166202 A AU1166202 A AU 1166202A AU 2002211662 A1 AU2002211662 A1 AU 2002211662A1
Authority
AU
Australia
Prior art keywords
kappab inhibitors
kappab
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211662A
Inventor
James F. Callahan
Amy K. Roshak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002211662A1 publication Critical patent/AU2002211662A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002211662A 2000-10-12 2001-10-12 Nf-kappab inhibitors Abandoned AU2002211662A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23976000P 2000-10-12 2000-10-12
US60239760 2000-10-12
PCT/US2001/031865 WO2002030423A1 (en) 2000-10-12 2001-10-12 NF-λB INHIBITORS

Publications (1)

Publication Number Publication Date
AU2002211662A1 true AU2002211662A1 (en) 2002-04-22

Family

ID=22903605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211662A Abandoned AU2002211662A1 (en) 2000-10-12 2001-10-12 Nf-kappab inhibitors

Country Status (4)

Country Link
EP (1) EP1328272A1 (en)
JP (1) JP2004532797A (en)
AU (1) AU2002211662A1 (en)
WO (1) WO2002030423A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4285602B2 (en) 2000-10-26 2009-06-24 アムジェン インコーポレイテッド Anti-inflammatory agent
AU2002352519A1 (en) * 2001-11-09 2003-05-26 The General Hospital Corporation Methods for treating ischemic reperfusion injury using ikb kinase-beta inhibitors
WO2003048152A2 (en) 2001-12-05 2003-06-12 Tularik Inc. Inflammation modulators
US7528161B2 (en) 2002-05-31 2009-05-05 Michigan State University NF-kappaB inhibitors and uses thereof
US6878735B2 (en) * 2002-05-31 2005-04-12 Board Of Trustees Of Michigan State University Multi-substituted imidazolines and method of use thereof
US7345078B2 (en) * 2002-05-31 2008-03-18 The Board Of Trustees Of Michigan State University NF-κB inhibitors and uses thereof
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
AR050253A1 (en) 2004-06-24 2006-10-11 Smithkline Beecham Corp COMPOSITE DERIVED FROM INDAZOL CARBOXAMIDE, COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
PE20060748A1 (en) 2004-09-21 2006-10-01 Smithkline Beecham Corp INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2
CA2613068A1 (en) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
PE20081889A1 (en) 2007-03-23 2009-03-05 Smithkline Beecham Corp INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
CN104491864A (en) 2008-04-21 2015-04-08 奥德纳米有限公司 Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR101323448B1 (en) 2008-10-02 2013-11-27 아사히 가세이 파마 가부시키가이샤 8-substituted isoquinoline derivative and use thereof
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319840A (en) * 1970-08-27 1973-06-13 Beecham Group Ltd Substituted 5-amino imidazoles
EP0963371B1 (en) * 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase

Also Published As

Publication number Publication date
EP1328272A1 (en) 2003-07-23
JP2004532797A (en) 2004-10-28
WO2002030423A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001237041A1 (en) Kinase inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
AU2003300832A1 (en) NF-KappaB INHIBITORS
AU4882101A (en) Mmp-12 inhibitors
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2001234088A1 (en) TNF-alpha inhibitors
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU5248800A (en) Fading inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001294557A1 (en) Thrombin inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2002222627A1 (en) Tak1 inhibitors
AU2001255090A1 (en) Cdk inhibitors having 3-hydroxychromen-4-one structure
AU3235100A (en) Prothease inhibitors
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2002224550A1 (en) Corrosion inhibitors
GB0030284D0 (en) Enzyme inhibitors
AU2003224941A1 (en) NF-KappaB INHIBITORS